TY - JOUR
T1 - Definition and classification of cancer cachexia
T2 - An international consensus
AU - Fearon, Kenneth
AU - Strasser, Florian
AU - Anker, Stefan D.
AU - Bosaeus, Ingvar
AU - Bruera, Eduardo
AU - Fainsinger, Robin L.
AU - Jatoi, Aminah
AU - Loprinzi, Charles
AU - MacDonald, Neil
AU - Mantovani, Giovanni
AU - Davis, Mellar
AU - Muscaritoli, Maurizio
AU - Ottery, Faith
AU - Radbruch, Lukas
AU - Ravasco, Paula
AU - Walsh, Declan
AU - Wilcock, Andrew
AU - Kaasa, Stein
AU - Baracos, Vickie E.
N1 - Funding Information:
MM has received speaking honoraria from Abbott, Baxter, Fresenius Kabi, Nestlé, and Nutricia. NM has received honoraria from Abbott, Millennium Pharmaceuticals and Tofts Epsom, and grant funding from Immunotec Solvay. SDA has received honoraria for advisory board membership from Novartis, and consultancy fees from Myotec Therapeutics. All other authors declared no conflicts of interest.
Funding Information:
This work was supported by the European Palliative Care Research Collaborative (EPCRC), an EU Framework 6 funded consortium ( LSHC-CT-2006-037777 ). The travel support of academic cachexia experts was provided for the first focus-group meeting by the Multinational Association of Supportive Care in Cancer (MASCC), for the second by the fourth cachexia conference, and for meetings associated with the EPCRC (FS, VB, KF) by the European Union and the Norwegian University at Trondheim.
PY - 2011/5
Y1 - 2011/5
N2 - To develop a framework for the definition and classification of cancer cachexia a panel of experts participated in a formal consensus process, including focus groups and two Delphi rounds. Cancer cachexia was defined as a multifactorial syndrome defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. Its pathophysiology is characterised by a negative protein and energy balance driven by a variable combination of reduced food intake and abnormal metabolism. The agreed diagnostic criterion for cachexia was weight loss greater than 5%, or weight loss greater than 2% in individuals already showing depletion according to current bodyweight and height (body-mass index [BMI] <20 kg/m2) or skeletal muscle mass (sarcopenia). An agreement was made that the cachexia syndrome can develop progressively through various stages-precachexia to cachexia to refractory cachexia. Severity can be classified according to degree of depletion of energy stores and body protein (BMI) in combination with degree of ongoing weight loss. Assessment for classification and clinical management should include the following domains: anorexia or reduced food intake, catabolic drive, muscle mass and strength, functional and psychosocial impairment. Consensus exists on a framework for the definition and classification of cancer cachexia. After validation, this should aid clinical trial design, development of practice guidelines, and, eventually, routine clinical management.
AB - To develop a framework for the definition and classification of cancer cachexia a panel of experts participated in a formal consensus process, including focus groups and two Delphi rounds. Cancer cachexia was defined as a multifactorial syndrome defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. Its pathophysiology is characterised by a negative protein and energy balance driven by a variable combination of reduced food intake and abnormal metabolism. The agreed diagnostic criterion for cachexia was weight loss greater than 5%, or weight loss greater than 2% in individuals already showing depletion according to current bodyweight and height (body-mass index [BMI] <20 kg/m2) or skeletal muscle mass (sarcopenia). An agreement was made that the cachexia syndrome can develop progressively through various stages-precachexia to cachexia to refractory cachexia. Severity can be classified according to degree of depletion of energy stores and body protein (BMI) in combination with degree of ongoing weight loss. Assessment for classification and clinical management should include the following domains: anorexia or reduced food intake, catabolic drive, muscle mass and strength, functional and psychosocial impairment. Consensus exists on a framework for the definition and classification of cancer cachexia. After validation, this should aid clinical trial design, development of practice guidelines, and, eventually, routine clinical management.
UR - http://www.scopus.com/inward/record.url?scp=79955399340&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(10)70218-7
DO - 10.1016/S1470-2045(10)70218-7
M3 - Review article
C2 - 21296615
AN - SCOPUS:79955399340
SN - 1470-2045
VL - 12
SP - 489
EP - 495
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 5
ER -